The tumor specimen was sent for further analysis for next-generation sequencing (NGS; ACTOnco+, ACT Genomics), which mainly disclosed TPM3::NTRK fusion (Appendix Fig A1), and MDM2/CDK4 gene amplification. The gene discussed is TPM3; the disease is neoplasm.